Review



skm1 cell line  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    DSMZ skm1 cell line
    Skm1 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/skm+1/us12171744-466-64-95
    Average 90 stars, based on 1 article reviews
    skm1 cell line - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Virus:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Recombinant:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Kinase Assay:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Transfection:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    cDNA Synthesis:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Mutagenesis:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    SYBR Green Assay:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Plasmid Preparation:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Software:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Cell Culture:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Control:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Concentration Assay:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Staining:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Western Blot:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Microscopy:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Phospho-proteomics:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    DNA Synthesis:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Incubation:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Radioactivity:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.

    Mass Spectrometry:

    Article Title: Pharmaceutical combinations for the treatment of cancer
    Article Snippet: TABLE 1 Cell line Culture conditions in 5% Name Vendor CO2/37 deg C. DLBCL cell lines RIVA DSMZ, Germany RPMI 1640 (Thermofisher) + 10% (or RI-1) FBS SU-DHL-4 ATCC, USA RPMI 1640 (Thermofisher) + 10% FBS U2932 DSMZ RPMI 1640 (Thermofisher) + 10% FBS NUDHL 1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS TOLEDO DSMZ RPMI 1640 (Thermofisher) + 10% FBS OCI Ly10 UHN, Princess IMDM (Thermofisher) + 20% Margaret human serum (Valley biomedical)- Hospital, Canada fresh media every passage INBC cell line HCC1187 ATCC RPMI 1640 (Thermofisher) + 10% FBS AML cell lines SKM1 DSMZ RPMI 1640 (Thermofisher) + 10% FBS MV-4-11 ATCC IMDM (Thermofisher) + 20% human serum (Valley biomedical) OCI AML3 DSMZ RPMI 1640 (Thermofisher) + 10% FBS For all Western Blot Analysis studies, the materials and methods outlined below were used.

    Article Title: Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
    Article Snippet: SKM1, MV4:11, LNCaP and OVCAR8 cell lines were purchased from ATCC or DSMZ and maintained by a Core Cell Line Facility.

    Article Title: Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors
    Article Snippet: SKM1 (gender: male) , DSMZ , Cat# ACC 547.



    Similar Products

    skm1 cell line  (DSMZ)
    90
    DSMZ skm1 cell line
    Skm1 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/skm+1/us12171744-466-64-95
    Average 90 stars, based on 1 article reviews
    skm1 cell line - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    skm1 cell line  (JCRB Cell Bank)
    90
    JCRB Cell Bank skm1 cell line
    a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the <t>SKM1</t> and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.
    Skm1 Cell Line, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/skm+1/pmc08993889-166-0-1
    Average 90 stars, based on 1 article reviews
    skm1 cell line - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    fbs aml cell lines skm1 dsmz rpmi 1640  (DSMZ)
    95
    DSMZ fbs aml cell lines skm1 dsmz rpmi 1640
    a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the <t>SKM1</t> and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.
    Fbs Aml Cell Lines Skm1 Dsmz Rpmi 1640, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/SKM-1/us11135198-468-90-95
    Average 95 stars, based on 1 article reviews
    fbs aml cell lines skm1 dsmz rpmi 1640 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    skm1 cell line  (FUJIFILM)
    90
    FUJIFILM skm1 cell line
    a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the <t>SKM1</t> and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.
    Skm1 Cell Line, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/skm1+azar++skm1+ar/pmc07836710-82-21-23
    Average 90 stars, based on 1 article reviews
    skm1 cell line - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    skm1 cell line  (Inserm Transfert)
    90
    Inserm Transfert skm1 cell line
    a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the <t>SKM1</t> and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.
    Skm1 Cell Line, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skm1+cell+line/skm1+cell+line/pm23085751-163-1-11
    Average 90 stars, based on 1 article reviews
    skm1 cell line - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the SKM1 and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.

    Journal: Cell Death Discovery

    Article Title: Targeting matrix metallopeptidase 2 by hydroxyurea selectively kills acute myeloid mixed-lineage leukemia

    doi: 10.1038/s41420-022-00989-4

    Figure Lengend Snippet: a Immunoblots of MLL (MLL C180 ) in the indicated cell lines. b ChIP analyses at the promoter region of the MMP2 locus in the SKM1 and THP1 cells. * P < 0.05; ** P < 0.01; the ns indicate no significant difference; two-tailed t- test. Data represent the means of triplicate reactions ± SD. c Cell viability of SKM1 was measured after 72-hour exposure to HU with co-treatment of 50 µM MM-102. d Cell viability was measured after 72-h exposure to triapine with co-treatment of 20 µM ilomastat. The IC 50 of different cells was quantified. e Cell viability of indicated cells with co-treatment of 50 µM HU and 150 nM triapine after 72 h. f immunofluorescence visualized the localization of endogenous MMP2 in SKM1 cells. Scale bar, 5 μm. g Venn diagram shows the number of candidates who interacted with MMP2 in SKM1 cells without or with the treatment of 100 μM HU after 24 h. h , i GO enrichment ( h ), and GSEA analysis ( i ) of the common 39 interaction candidates of MMP2 in SKM1 cells with or without HU treatment. j THP1 cells were transfected with full-length MMP2, with a 3× FLAG-tag. Cell fractions were prepared for the Co-IP assays using the indicated antibodies. k Relative protein synthesis of SKM1 and THP1 cells with HU treatment after the indicated hours.

    Article Snippet: SKM1 (JCRB cell bank, Osaka, Japan).

    Techniques: Western Blot, Two Tailed Test, Immunofluorescence, Transfection, FLAG-tag, Co-Immunoprecipitation Assay